Nutech Ventures

Creighton University

Nicholas Palermo

Sandor Lovas

Laura Hansen

Asit K Pattnaik

Shi-hua Xiang

Aryamav ' Pattnaik

Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3ε heterodimerization or CDC25A binding to 14-3-3ε. A peptide composition embodiment includes, but is not limited to, at least one of a first targeting peptide comprising a structure of Trp-Tyr-Trp-Lys-NH(SEQ ID NO: 1), a second targeting peptide comprising a structure of phospho-Ser178; Ac-Thr-Gln-Arg-Gln-Asn-Ser-(PO)-Ala-Pro-Arg-Met-Leu-Ser-Ser-Asn-NH(SEQ ID NO: 2), and a third targeting peptide comprising a structure of phospho-Thr507 residue; Ac-Arg-Thr-Lys-Ser-Arg-Thr(PO)-Trp-Ala-Gly-Glu-Lys-Ser-Lys-Arg-NH(SEQ ID NO: 3).

14-3-3 targeting peptides for cancer treatment

Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3&#x3b5; heterodimerization or CDC25A binding to 14-3-3&#x3b5;. A peptide composition embodiment includes, but is not limited to, at least one of a first targeting peptide comprising a structure of Ac-Gln-Arg-Gln-Asn-Ser-(PO)-Ala-Pro-Ala-Arg-NH(SEQ ID NO: 4) and a second targeting peptide comprising a structure of Ac-Arg-Thr-Lys-Ser-Arg-Thr(PO)-Trp-Ala-Gly-NH(SEQ ID NO: 5), and a third targeting peptide comprising a modification of or a substituted derivative of the peptide of SEQ ID NO: 4 or SEQ ID NO: 5.

Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3&#x3b5; heterodimerization or CDC25A binding to 14-3-3&#x3b5;. A peptide composition embodiment includes, but is not limited to, at least one of a first targeting peptide comprising a structure of Trp-Tyr-Trp-Lys-NH(SEQ ID NO: 1), a second targeting peptide comprising a structure of phospho-Ser178; Ac-Thr-Gln-Arg-Gln-Asn-Ser-(PO)-Ala-Pro-Arg-Met-Leu-Ser-Ser-Asn-NH(SEQ ID NO: 2), and a third targeting peptide comprising a structure of phospho-Thr507 residue; Ac-Arg-Thr-Lys-Ser-Arg-Thr(PO)-Trp-Ala-Gly-Glu-Lys-Ser-Lys-Arg-NH(SEQ ID NO: 3).

This document relates to methods and materials for treating a mammal having a Zika virus (ZIKV) infection. For example, a composition including one or more non-nucleoside RNA polymerase inhibitors can be administered to a mammal having, or at risk of developing, a ZIKV infection to treat the mammal

Growing community of inventors

Omaha, NE, United States of America

Nicholas Palermo